Jan Klysik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jan Klysik has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
John M. Sedivy
Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, USA
5 shared publicationsErin Paul
Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, 70 Ship St., Providence, RI 02903, USA
2 shared publicationsJeffrey S. Moffit
C Department of Pathology and Laboratory Medicine, Brown University, Providence, RI
2 shared publicationsKim Boekelheide
Department of Pathology and Laboratory Medicine, Brown University, Providence, USA
2 shared publications- Allan Bradley
Wellcome Sanger Institute, Hinxton, UK
1 shared publication Carlos Murga-Zamalloa
Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, USA
1 shared publication
Latest Publications
- 25 November 2009
- Published by Springer Nature in Transgenic Research
- Vol. 19 (4) , 691-701
Widespread expression of the Supv3L1 mitochondrial RNA helicase in the mouse
Supv3L1 is an evolutionarily conserved helicase that plays a critical role in the mitochondrial RNA surveillance and degradation machinery. Conditional ablation of Supv3L1 in adult mice leads to premature aging phenotypes including loss of muscle mass and adipose tissue and severe skin abnormalities. To get insights into the spatial and temporal expression of Supv3L1 in the mouse, we generated knock-in and transgenic strains in which an EGFP reporter was placed under control of the Supv3L1 native promoter. During development, expression of Supv3L1 begins at the blastocyst stage, becomes widespread and strong in all fetal tissues and cell types, and continues during postnatal growth. In mature animals reporter expression is only slightly diminished in most tissues and continues to be highly expressed in the brain, peripheral sensory organs, and testis. Together, these data confirm that Supv3L1 is an important developmentally regulated gene, which continues to be expressed in all mature tissues, particularly the rapidly proliferating cells of testes, but also in the brain and sensory organs. The transgenic mice and cell lines derived from them constitute a valuable tool for the examination of the spatial and temporal aspects of Supv3L1 promoter activity, and should facilitate future screens for small molecules that regulate Supv3L1 expression.
- 25 November 2009
- Published by Springer Nature in Transgenic Research
- Vol. 19 (4) , 691-701
Widespread expression of the Supv3L1 mitochondrial RNA helicase in the mouse
Supv3L1 is an evolutionarily conserved helicase that plays a critical role in the mitochondrial RNA surveillance and degradation machinery. Conditional ablation of Supv3L1 in adult mice leads to premature aging phenotypes including loss of muscle mass and adipose tissue and severe skin abnormalities. To get insights into the spatial and temporal expression of Supv3L1 in the mouse, we generated knock-in and transgenic strains in which an EGFP reporter was placed under control of the Supv3L1 native promoter. During development, expression of Supv3L1 begins at the blastocyst stage, becomes widespread and strong in all fetal tissues and cell types, and continues during postnatal growth. In mature animals reporter expression is only slightly diminished in most tissues and continues to be highly expressed in the brain, peripheral sensory organs, and testis. Together, these data confirm that Supv3L1 is an important developmentally regulated gene, which continues to be expressed in all mature tissues, particularly the rapidly proliferating cells of testes, but also in the brain and sensory organs. The transgenic mice and cell lines derived from them constitute a valuable tool for the examination of the spatial and temporal aspects of Supv3L1 promoter activity, and should facilitate future screens for small molecules that regulate Supv3L1 expression.
- 15 January 2009
- Published by Springer Nature in Mammalian Genome
- Vol. 20 (2) , 92-108
Disruption of Supv3L1 damages the skin and causes sarcopenia, loss of fat, and death
Supv3L1 is a conserved and ubiquitously expressed helicase found in numerous tissues and cell types of many species. In human cells, SUPV3L1 was shown to suppress apoptotic death and sister chromatid exchange, and impair mitochondrial RNA metabolism and protein synthesis. In vitro experiments revealed binding of SUPV3L1 to BLM and WRN proteins, suggesting a role in genome maintenance processes. Disruption of the Supv3L1 gene in the mouse has been reported to be embryonic lethal at early developmental stages. We generated a conditional mouse in which the phenotypes associated with the removal of exon 14 can be tested in a variety of tissues. Disruption mediated by a Mx1 promoter-driven Cre displayed a postnatal growth delay, reduced lifespan, loss of adipose tissue and muscle mass, and severe skin abnormalities manifesting as ichthyosis, thickening of the epidermis, and atrophy of the dermis and subcutaneous tissue. Using a tamoxifen-activatable Esr1/Cre driver, Supv3L1 disruption resulted in growth retardation and aging phenotypes, including loss of adipose tissue and muscle mass, kyphosis, cachexia, and premature death. Many of the abnormalities seen in the Mx1-Cre mice, such as hyperkeratosis characterized by profound scaling of feet and tail, could also be detected in tamoxifen-inducible Cre mice. Conditional ablation of Supv3L1 in keratinocytes confirmed atrophic changes in the skin and ichthyosis-like changes. Together, these data indicate that Supv3L1 is important for the maintenance of the skin barrier. In addition, loss of Supv3L1 function leads to accelerated aging-like phenotypes.
- 15 January 2009
- Published by Springer Nature in Mammalian Genome
- Vol. 20 (2) , 92-108
Disruption of Supv3L1 damages the skin and causes sarcopenia, loss of fat, and death
Supv3L1 is a conserved and ubiquitously expressed helicase found in numerous tissues and cell types of many species. In human cells, SUPV3L1 was shown to suppress apoptotic death and sister chromatid exchange, and impair mitochondrial RNA metabolism and protein synthesis. In vitro experiments revealed binding of SUPV3L1 to BLM and WRN proteins, suggesting a role in genome maintenance processes. Disruption of the Supv3L1 gene in the mouse has been reported to be embryonic lethal at early developmental stages. We generated a conditional mouse in which the phenotypes associated with the removal of exon 14 can be tested in a variety of tissues. Disruption mediated by a Mx1 promoter-driven Cre displayed a postnatal growth delay, reduced lifespan, loss of adipose tissue and muscle mass, and severe skin abnormalities manifesting as ichthyosis, thickening of the epidermis, and atrophy of the dermis and subcutaneous tissue. Using a tamoxifen-activatable Esr1/Cre driver, Supv3L1 disruption resulted in growth retardation and aging phenotypes, including loss of adipose tissue and muscle mass, kyphosis, cachexia, and premature death. Many of the abnormalities seen in the Mx1-Cre mice, such as hyperkeratosis characterized by profound scaling of feet and tail, could also be detected in tamoxifen-inducible Cre mice. Conditional ablation of Supv3L1 in keratinocytes confirmed atrophic changes in the skin and ichthyosis-like changes. Together, these data indicate that Supv3L1 is important for the maintenance of the skin barrier. In addition, loss of Supv3L1 function leads to accelerated aging-like phenotypes.
- Open Access
- 29 February 2008
- Published by Springer Nature in BMC Physiology
- Vol. 8 (1) , 4
Forced expression of the cell cycle inhibitor p57Kip2 in cardiomyocytes attenuates ischemia-reperfusion injury in the mouse heart
Background: Myocardial hypoxic-ischemic injury is the cause of significant morbidity and mortality worldwide. The cardiomyocyte response to hypoxic-ischemic injury is known to include changes in cell cycle regulators. The cyclin-dependent kinase inhibitor p57 Kip 2is involved in cell cycle control, differentiation, stress signaling and apoptosis. In contrast to other cyclin-dependent kinase inhibitors, p57Kip2 expression diminishes during postnatal life and is reactivated in the adult heart under conditions of cardiac stress. Overexpression of p57 Kip 2has been previously shown to prevent apoptotic cell death in vitro by inhibiting stress-activated kinases. Therefore, we hypothesized that p57 Kip 2has a protective role in cardiomyocytes under hypoxic conditions. To investigate this hypothesis, we created a transgenic mouse (R26loxpTA-p57 k/+) that expresses p57Kip2 specifically in cardiac tissue under the ventricular cardiomyocyte promoter Mlc2v. Results: Transgenic mice with cardiac specific overexpression of p57 Kip 2are viable, fertile and normally active and their hearts are morphologically indistinguishable from the control hearts and have similar heart weight/body weight ratio. The baseline functional parameters, including left ventricular systolic pressure (LVSP), left ventricular end diastolic pressure (LVEDP), LVdp/dtmax, heart rate (HR) and rate pressure product (RPR) were not significantly different between the different groups as assessed by the Langendorff perfused heart preparation. However, after subjecting the heart ex vivo to 30 minutes of ischemia-reperfusion injury, the p57 Kip 2overexpressing hearts demonstrated preserved cardiac function compared to control mice with higher left ventricular developed pressure (63 ± 15 vs 30 ± 6 mmHg, p = 0.05), rate pressure product (22.8 ± 4.86 vs 10.4 ± 2.1 × 103bpm × mmHg, p < 0.05) and coronary flow (3.5 ± 0.5 vs 2.38 ± 0.24 ml/min, p Kip2 does not affect myocardial growth, differentiation and baseline function but attenuates injury from ischemia-reperfusion in the adult mouse heart.
- 29 February 2008
- Published by Springer Nature in BMC Physiology
- Vol. 8 (1) , 4
Open AccessForced expression of the cell cycle inhibitor p57Kip2 in cardiomyocytes attenuates ischemia-reperfusion injury in the mouse heart
Background: Myocardial hypoxic-ischemic injury is the cause of significant morbidity and mortality worldwide. The cardiomyocyte response to hypoxic-ischemic injury is known to include changes in cell cycle regulators. The cyclin-dependent kinase inhibitor p57 Kip 2is involved in cell cycle control, differentiation, stress signaling and apoptosis. In contrast to other cyclin-dependent kinase inhibitors, p57Kip2 expression diminishes during postnatal life and is reactivated in the adult heart under conditions of cardiac stress. Overexpression of p57 Kip 2has been previously shown to prevent apoptotic cell death in vitro by inhibiting stress-activated kinases. Therefore, we hypothesized that p57 Kip 2has a protective role in cardiomyocytes under hypoxic conditions. To investigate this hypothesis, we created a transgenic mouse (R26loxpTA-p57 k/+) that expresses p57Kip2 specifically in cardiac tissue under the ventricular cardiomyocyte promoter Mlc2v. Results: Transgenic mice with cardiac specific overexpression of p57 Kip 2are viable, fertile and normally active and their hearts are morphologically indistinguishable from the control hearts and have similar heart weight/body weight ratio. The baseline functional parameters, including left ventricular systolic pressure (LVSP), left ventricular end diastolic pressure (LVEDP), LVdp/dtmax, heart rate (HR) and rate pressure product (RPR) were not significantly different between the different groups as assessed by the Langendorff perfused heart preparation. However, after subjecting the heart ex vivo to 30 minutes of ischemia-reperfusion injury, the p57 Kip 2overexpressing hearts demonstrated preserved cardiac function compared to control mice with higher left ventricular developed pressure (63 ± 15 vs 30 ± 6 mmHg, p = 0.05), rate pressure product (22.8 ± 4.86 vs 10.4 ± 2.1 × 103bpm × mmHg, p < 0.05) and coronary flow (3.5 ± 0.5 vs 2.38 ± 0.24 ml/min, p Kip2 does not affect myocardial growth, differentiation and baseline function but attenuates injury from ischemia-reperfusion in the adult mouse heart.
- 1 January 2008
- Published by Elsevier in Cellular Signalling
- Vol. 20 (1) , 1-9
Signaling crossroads: The function of Raf kinase inhibitory protein in cancer, the central nervous system and reproduction
- 1 January 2008
- Published by Elsevier in Cellular Signalling
- Vol. 20 (1) , 1-9
Signaling crossroads: The function of Raf kinase inhibitory protein in cancer, the central nervous system and reproduction
- Open Access
- 3 July 2007
- Published by Wiley in Journal of Andrology
- Vol. 28 (6) , 883-890
Mice Lacking Raf Kinase Inhibitor Protein-1 (RKIP-1) Have Altered Sperm Capacitation and Reduced Reproduction Rates With a Normal Response to Testicular Injury
- 3 July 2007
- Published by Wiley in Journal of Andrology
- Vol. 28 (6) , 883-890
Open AccessMice Lacking Raf Kinase Inhibitor Protein-1 (RKIP-1) Have Altered Sperm Capacitation and Reduced Reproduction Rates With a Normal Response to Testicular Injury
- 1 March 2007
- Published by Elsevier in Brain Research Bulletin
- Vol. 71 (6) , 559-567
Raf kinase inhibitory protein knockout mice: Expression in the brain and olfaction deficit
- 1 March 2007
- Published by Elsevier in Brain Research Bulletin
- Vol. 71 (6) , 559-567
Raf kinase inhibitory protein knockout mice: Expression in the brain and olfaction deficit
- 1 June 2005
- Published by Springer Nature in Biochemical Genetics
- Vol. 43 (5-6) , 321-333
Mice with the Enhanced Green Fluorescent Protein Gene Knocked in to Chromosome 11 Exhibit Normal Transmission Ratios
- 1 June 2005
- Published by Springer Nature in Biochemical Genetics
- Vol. 43 (5-6) , 321-333
Mice with the Enhanced Green Fluorescent Protein Gene Knocked in to Chromosome 11 Exhibit Normal Transmission Ratios
- 1 March 2004
- Vol. 16 (93) , 205-7
[Functional genomics and its impact on the future medicine].
The sequencing of the human genome was completed in 2003. These data will affect all aspects of biological and medical sciences. Since almost all the genes of the genome are known, the diagnosis and therapy of the future is expected to evolve towards more personalized and efficient methods. Before these medical advancements become applicable, functional genomics must successfully determine the cellular role all the genes in the genome. Comprehensive functional studies will require suitable animal models. Although many mammalian species are used in biological and medical experiments, the mouse emerges as a key model organism in studies of human genes. The power of the mouse model system comes from its extensive physiological and pathological similarities to humans and from technological advancements offered by mouse genetics. Recently, a project called ENCODE was launched to accelerate this monumental effort of gene analysis. Once gene analysis is completed, the face of medicine will change markedly. The greatest impact is expected on the front of individual diagnosis of disease genes and personalized treatments of patients.
- 1 March 2004
- Vol. 16 (93) , 205-7
[Functional genomics and its impact on the future medicine].
The sequencing of the human genome was completed in 2003. These data will affect all aspects of biological and medical sciences. Since almost all the genes of the genome are known, the diagnosis and therapy of the future is expected to evolve towards more personalized and efficient methods. Before these medical advancements become applicable, functional genomics must successfully determine the cellular role all the genes in the genome. Comprehensive functional studies will require suitable animal models. Although many mammalian species are used in biological and medical experiments, the mouse emerges as a key model organism in studies of human genes. The power of the mouse model system comes from its extensive physiological and pathological similarities to humans and from technological advancements offered by mouse genetics. Recently, a project called ENCODE was launched to accelerate this monumental effort of gene analysis. Once gene analysis is completed, the face of medicine will change markedly. The greatest impact is expected on the front of individual diagnosis of disease genes and personalized treatments of patients.